Effect of intranasal mometasone furoate administered in children with coexisting allergic rhinitis and asthma towards asthma attacks and lung function
Abstract
Background Allergic rhinitis and asthma are allergic manifestations in respiratory tract, which related each other. Intranasal corticosteroid is effective in allergic rhinitis and has benefits in decreasing lower airway reactivity.Objectives To evaluate effectiveness of intranasal mometasone
furoate towards asthma in children aged 6-18 years with coexisting allergic rhinitis and asthma.
Methods A one group pretest-posttest ("before and after") study was conducted in Cipto Mangunkusumo Hospital from May to December 2008. Subjects were children aged 6-18 years, with moderate-severe intermittent or persistent allergic rhinitis with coexisting frequent episodic asthma or persistent asthma, and visited outpatient clinic of allergy immunology division or respirology division. Subjects were administered intranasal mometasone furoate 100 J-ig daily only for 8 weeks, without long term administration of oral and inhaled corticosteroid. Improvements in allergic rhinitis and asthma were evaluated using questionnaires and lung function tests.
Results There were 35 subjects and four of them dropped out
during the study. There was >50% improvement in allergic rhinitis symptoms after 4 weeks of treatment (P<0.001). This improvement was associated with decreasing in frequency of asthma attack >50% after 8 weeks of treatment (P< 0.001). There was an insignificant improvement in FEY 1 (P=0.51). However, the evaluation of sinusitis was not performed in all subjects, thus may influence the results. During study, there were no side effects observed.
Conclusions Intranasal mometasone furoate improves allergic
rhinitis and decrease >50% of asthma symptoms, however it is not followed with significant improvement in lung function. No side effects are reported during 8 weeks use of intranasal mometasone furoate.
References
to emerging therapies. Indian J Chest Dis Allied Sci.
2003;45: 179-89.
2. Scadding GK. Corticosteroids in the treatment of pediatric
allergic rhinitis. J Allergy Clin lmmunol. 2001; 108:S59-64.
3. Kulig M, Klettke U, Wahn V, Forster J, Bauer CP, Wahn
U, MAS Study Group. Development of seasonal allergic
rhinitis during the first 7 years oflife. J Allergy Clin Immunol.
2000; 106:83 2-9.
4. Lack G. Pediatric allergic rhinitis and comorbid disorders. J
Allergy Clin Immunol. 2001; 108:S9-15.
5. Terr AI. The atopic diseases. In: Parslow TG, Stites DP, Terr
AI, Imboden JB, penyunting. Medical immunology. lO'h ed.
Boston: McGraw Hill, 2003; p.349-69.
6. Braunstahl GJ, Overbeek SE, Kleinjan A, Prius JB,
Hoogsteden HC, Fokkens WJ. Nasal allergen provocation
induces adhesion molecule expression and tissue eosinophilia
in upper and lower airways. J Allergy Clin Immunol.
2001; 1107:469-76.
7. Fontanari P, Burnet H, Zattara-Harmann MO, James Y.
Changes in airway resistance induced by nasal inhalation
of cold dry, dry, or moist air in normal individuals. J Appl
Physiol.1996;81:1739-43.
8. Henriksen JW, Wenzel A. Effect of an intranasally
administered corticosteroid (budesonide) on nasal obstruction,
mouth breathing and asthma. Am Rev Respir Dis.
1984; 130:1013-8.
9. Watson WIA, Becker AH, Simon FER. Treatment of allergic
rhinitis with intranasal corticosteroids in patients with mild
asthma: effect on lower airway responsiveness. J Allergy Clin
Immunol. 1993;91:97 -101.
10. Taramarcaz P, Gibson PG. Intranasal corticosteroids for
asthma control in people with coexisting asthma and rhinitis.
[Cochrane review]. In: The Cochrane Library, Issue 3, 2003.
Oxford: Update Software.
11. Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol. 2001;108:S54-8.
12. Trangsrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy. 2002;22: 1458-67.
13. Rachelefsky GS, Katz RM, Siegel SC. Chronic sinus disease
with associated reactive airway disease in children. Pediatrics.
1984;73:526-29.
14. Meltzer EO, J alowayski M, Orgel A, Harris AG. Subjective
and objective assessments in patients with seasonal allergic
rhinitis: effects of therapy with mometasone furoate nasal
spray. J Allergy Clin Immunol. 1998; 102:39-49.
15. Bousquet], van Cauwenberge P, Khaltaev N. Allergic rhinitis
and its impact on asthma. ARIA workshop report. J Allergy
Clin Immunol. 2001;108:S147-276.
16. Bronsky E, Boggs P, Findlay S, Gawchik S, Georgitis J,
Mansmann H, dkk. Comparative efficacy and safety of a
once-daily loratadine-pseudoephedrine combination versus its
components alone and placebo in the management of seasonal
allergic rhinitis. J Allergy Clin Immunol. 1995 ;96: 139-4 7.
17. UKK Pulmonologi. Pedoman nasional asma anak. In: Rahajoe
N, Supriyatno B, Setyanto DB, editors. Jakarta: PP IDAI,
2004; p. 1-44.
18. Pediatric asthma symptom score [homepage on the internet].
c2000 [cited 2007 Nov 15]. Available from: http://www.rand.org.
19. Weiner JM, Abramson MJ, Poy RM. Intranasal corticosteroids
versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials. BMJ. 1998;317:1624-9.
20. Penagos M, Compalati E, Tarantini F, Baena-Cagnani CE,
Passalacqua G, Canonica GW: Efficacy of mometasone
furoate nasal spray in the treatment of allergic rhinitis: metaanalysis of randomized, double blind, pacebo-controlled,
clinical trials. Allergy. 2008;63: 1280-91.
21. Peters JC, Neslusan C, Crown WH, Torres A. Treating allergic
rhinitis in patients with comorbid asthma: the risk of asthmarelated hospitalizations and emergency department visit. J
Allergy Clin Immunol. 2002; 109:57-62.
22. Corren J, Manning BE, Thompson SF, Hennesy S, Strom
B. Rhinitis therapy and the prevention of hospital care
for asthma: a case control study. J Allergy Clin Immunol.
2004;113:415-9.
23. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM.
Asthma, from bronchoconstriction to airways inflammation and
remodeling. Am] Respir Cri Care Med. 2000;161:1 720-45.
24. Jeffery PK, Haahtela T. Allergic rhinitis and asthma:
inflammation in one-airway condition. BMC Pulm Med.
2006;6:S5-16.
25. Payne DNR, Rogers A V, Adelroth E, Bandi V, Guntupalli KK,
Bush A, dkk. Early thickening of the reticular membrane in
children with difficult astnma. Am J Respir Crit Care Med.
2003;167:78-82.
26. Mauad T, Bel EH, Sterk PJ. Asthma therapy and airway
remodeling. J Allergy Clin Immunol. 2007; 120:997-1009.
27. Reddel HK, Belousova EG, Marks GB, Jenkins C. Does
continuous use of inhaled corticosteroids improve outcomes
in mild asthma? A double-blind randomized controlled trial.
Prim Care Respir J. 2008; 17:39-45.
28. Ramsdell JQ, Nayak AS, Bensch GW: Efficacy of treatment
with oncedaily evening dosing of mometasone furoate dry
powder inhaler 200 micrograms in asthma stratified by
baseline severity. Am J Respir Crit Care Med. 2009; 179: 19-24.
29. Camargos P, Ibiapina C, Lasmar I, Cruz AA. Obtaining
concomitant control of allergic rhinitis and asthma with a
nasally inhaled corticosteroid. Allergy. 2007 ;62:31 0-6.
30. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA,
Stauffer JL, Philpot E, et al. Fluticasone propionate nasal
spray is superior to montelukast for allergic rhinitis while
neither affects overall asthma control. Chest. 2005; 128:1910-20.
31. Lumry WR. A review of the preclinical and clinical data of
newer intranasal steroids used in the treatment of allergic
rhinitis. J Allergy Clin Immunol. 1999; 104:150-8.
32. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman
DS, Rooklin A, et a!. Absence of growth retardation in
children with perennial allergic rhinitis after one year of
treatment with mometasone furoate aqueous nasal spray.
Pediatrics. 2000; 105:22-9.
33. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin
DJ, Finn AF, et a!. A dose-ranging study of mometasone
furoate aqueous nasal spray in children with seasonal allergic
rhinitis. J Allergy Clin Immunol. 1999; 104:107-14.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2016-09-12
Published 2009-12-31